AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26727076
Drug: NNC0195‐0092 (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0195‐0092 (0.12 mg/kg)
Trial: 26727076
Drug: NNC0195‐0092 (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0195‐0092 (0.02 mg/kg and 0.04 mg/kg)
Trial: 24535604
Drug: SPI-guided analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-guided analgesia (sufentanil bolus 10 μg when SPI > 50)
Trial: 24535604
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice (sufentanil administered according to standard clinical practice)
Trial: 22798536
Drug: Cholecalciferol 10,333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 10,333 IU weekly
Trial: 20109743
Drug: SQ-standardized grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-standardized grass allergy immunotherapy tablet Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU)
Trial: 24160483
Drug: Monthly reminders
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly reminders for sit-to-stand activity
Trial: 27770145
Drug: 186Re-HEDP administered
RxNorm normalized name: HEDP
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 186Re-HEDP administered at levels above 3.5 GBq
Trial: 27770145
Drug: Patient mean
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient mean absorbed dose
Trial: 27770145
Drug: Whole-body absorbed
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body absorbed dose
Trial: 12161476
Drug: Daily hGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hGH therapy (6 mg/m2 weekly)
Trial: 12161476
Drug: Alternate day
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate day hGH therapy (6 mg/m2 weekly)
Trial: 12161476
Drug: Cumulative growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative growth velocity over 4 years (2 years on and 2 years off therapy)
Trial: 2140030
Drug: Prochlorperazine 5
RxNorm normalized name: prochlorperazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 5 mg intravenously
Trial: 30664895
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with 6 months of androgen deprivation therapy
Trial: 30664895
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy without androgen deprivation therapy
Trial: 16289980
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 1000 microg bid
Trial: 18237866
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (P)
Trial: 14695986
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxa treatment at therapeutic points
Trial: 8818850
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg three times daily for 10 days)
Trial: 1430361
Drug: 15% paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% paromomycin sulfate and 12% methylbenzethonium chloride (15/12 P-ointment)
Trial: 1430361
Drug: 15% paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% paromomycin sulfate and 5% methylbenzethonium chloride (15/5 P-ointment)
Trial: 6100870
Drug: Enalapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-40 mg q.d.)
Trial: 6100870
Drug: Enalapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-40 mg q.d.) + Hydrochlorothiazide (50 mg/day)
Trial: 6100870
Drug: Enalapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (40 mg) + Hydrochlorothiazide (50, 25, 12.5 mg/day)
Trial: 28766879
Drug: Bivalirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (bolus 0.75 mg/kg followed by infusion of 1.75 mg/kg, extra bolus 0.3 mg/kg before stenting)
Trial: 28766879
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH, 100 IU/kg)
Trial: 26382728
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg oral ibrutinib, fasting conditions
Trial: 26382728
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg oral ibrutinib, fed, after glucose drink
Trial: 26382728
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg oral ibrutinib, fed, with grapefruit juice before dosing
Trial: 16943370
Drug: Rizatriptan 5
RxNorm normalized name: rizatriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 5 mg
Trial: 10220208
Drug: NPH-insulin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH-insulin (0.3 U/kg)
Trial: 7045975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Telepaque and Bilopaque (TF-B)
Trial: 7045975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Telepaque given with food (TF) and Telepaque given without food (TF-TF)
Trial: 7045975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Telepaque given without food (T) and Telepaque given without food (T-T)
Trial: 31368269
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication (Tamsulosin 0.2 mg/d for 8 weeks)
Trial: 31368269
Drug: Medication (Tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Tamsulosin 0.2 mg/d for 8 weeks)
Trial: 20139678
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation timing and dose
Trial: 18341564
Drug: Lidocaine 20%
RxNorm normalized name: lidocaine 20% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20% patch (DentiPatch)
Trial: 12386637
Drug: Fixed 800
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed 800 mg/d ribavirin
Trial: 12386637
Drug: Body weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight-based 800/1000/1200 mg/d ribavirin
Trial: 12386637
Drug: 13 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 mg/kg per day ribavirin
Trial: 7561805
Drug: PM vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM vaccine (Pasteur Mérieux)
Trial: 7561805
Drug: SKB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKB vaccine (Smith‐Kline Beecham)
Trial: 2140854
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg loading dose: 4 mg IV plus 4 mg orally, followed by 8 mg every 8 hours orally for 3 to 5 days)
Trial: 2140854
Drug: Metoclopramide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (80 mg loading dose: 60 mg IV plus 20 mg orally, followed by 20 mg every 8 hours orally for 3 to 5 days)
Trial: 30569245
Drug: AB928 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB928 (10 to 200 mg once daily and 100 mg twice daily)
Trial: 23835673
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 μg/kg)
Trial: 23507173
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g GOS (Control)
Trial: 23507173
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g GOS
Trial: 23507173
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g GOS
Trial: 21205361
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural body image therapy (10 group sessions)
Trial: 19667282
Drug: 6-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-month therapy
Trial: 19667282
Drug: 9-month therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-month therapy
Trial: 15276392
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg/day) + Clopidogrel (75 mg/day)
Trial: 15276392
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day) alone
Trial: 11689577
Drug: Capecitabine 1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 1,250 mg/m² administered twice daily days 1 to 14 every 3 weeks
Trial: 11689577
Drug: Intravenous 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous 5-FU plus leucovorin (5-FU/LV)
Trial: 31078146
Drug: M4E4 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M4E4 primer combination
Trial: 31078146
Drug: M2E3 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2E3 primer combination
Trial: 31078146
Drug: M4E3 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M4E3 primer combination
Trial: 31078146
Drug: M3E1 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3E1 primer combination
Trial: 31078146
Drug: M2E4 primer
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2E4 primer combination
Trial: 29873529
Drug: HTX-019 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 130 mg (30-min infusion)
Trial: 29873529
Drug: fosaprepitant 150
RxNorm normalized name: fosaprepitant 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosaprepitant 150 mg (20- or 30-min infusion)
Trial: 20081109
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (0.7 pmol.kg(‐1).min(‐1))
Trial: 26540491
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 2.5 or 5 μg
Trial: 23992515
Drug: Tiotropium HandiHaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium HandiHaler 18 μg
Trial: 23913464
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control strategy (antiarrhythmic medication and/or electrical cardioversion)
Trial: 17090821
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow mesenchymal stem cell therapy
Trial: 15001902
Drug: Phenoxybenzamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine 0.25 mg/kg on cardiopulmonary bypass
Trial: 9374816
Drug: High hydration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hydration (HighH) - 2.0 ml water/kg body weight every 30 min
Trial: 9374816
Drug: Low hydration
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hydration (LowH) - 0.25 ml water/kg body weight every 30 min
Trial: 3539523
Drug: PEEP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP titration based on PaO2 < 65 torr with FIO2 of 0.45
Trial: 3539523
Drug: PEEP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP titration until PaO2/FIO2 > 300 or Qsp/Qt < 0.20
Trial: 28603468
Drug: Formulated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated milk product containing 9 g milk protein (FMP)
Trial: 18327986
Drug: darunavir/r (600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/r (600/100 mg bid)
Trial: 16801663
Drug: Haplotypes ‐2578‐A/‐1154‐A/‐634‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotypes ‐2578‐A/‐1154‐A/‐634‐G or ‐2578‐A/‐1154‐G/‐634‐G in the VEGF gene
Trial: 10946892
Drug: 1% T
RxNorm normalized name: OPIUM 1% TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% T gel (50 or 100 mg/day)
Trial: 10946892
Drug: 1% T
RxNorm normalized name: OPIUM 1% TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% T gel (100 mg/day)
Trial: 10946892
Drug: 1% T
RxNorm normalized name: OPIUM 1% TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% T gel (50 mg/day)
Trial: 10946892
Drug: T patch
RxNorm normalized name: Icy Hot Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T patch (5 mg/day)
Trial: 10946892
Drug: 1% T
RxNorm normalized name: OPIUM 1% TINCTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% T gel
Trial: 15477371
Drug: T patch
RxNorm normalized name: Icy Hot Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T patch
Trial: 1457767
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg three times daily)
Trial: 6749206
Drug: Conventional high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional high-dose prednisone
Trial: 6749206
Drug: Cytotoxic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic drugs
Trial: 25666998
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200mg/mL weekly for five weeks)
Trial: 23085502
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy home program (OTHP) for 20 weeks, average 15 min per session
Trial: 21095115
Drug: CNS-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS-directed therapy with intravenous methotrexate (5 g/sqm) in 4-10 courses and intrathecal methotrexate injections (10-20), no cranial irradiation.
Trial: 19011778
Drug: Low-molecular-weight hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight hydroxyethyl starch (HES) at 2 ml x kg(‐1) x h(‐1) during surgery and 1 ml x kg(‐1) x h(‐1) after surgery, plus acetated Ringer's solution (AR) to maintain CVP at 5 mm Hg
Trial: 19011778
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution (AR) to maintain CVP at 3-5 mmHg
Trial: 19011778
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution (AR)
Trial: 16980114
Drug: Inactivated whole-virion
RxNorm normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated whole-virion influenza A (H5N1) vaccine with 1.25 microg (24), 2.5 microg (24), 5 microg (24), or 10 microg (24) haemagglutinin per dose with aluminium hydroxide adjuvant
Trial: 10676669
Drug: L-arginine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 9 g daily for one month
Trial: 26331581
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg single oral dose administered twice to subjects with ESRD, once before hemodialysis and once after hemodialysis)
Trial: 26331581
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg single oral dose administered before and after hemodialysis)
Trial: 26331581
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg single oral dose)
Trial: 21626819
Drug: Axamon (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axamon (20 mg 3 times a day for 12 weeks)
Trial: 15896281
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus continued psychopharmacology
Trial: 11735172
Drug: levamisole/UFT chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole/UFT chemotherapy (N=29)
Trial: 9440632
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day lansoprazole
Trial: 8306000
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEDLINE and selective hand search
Trial: 3597149
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy and misonidazole (1.5 gm/m2 daily 4‐6 hr before each treatment)
Trial: 3597149
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy and misonidazole
Trial: 30092666
Drug: 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg dexmedetomidine via intravenous pump
Trial: 18692841
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LDA) 100 mg daily
Trial: 18692841
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids 4 g daily
Trial: 17229604
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream monotherapy (Group B)
Trial: 17229604
Drug: Combined ablation
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ablation followed by topical imiquimod (Group C)
Trial: 12663600
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg (A10)
Trial: 12663600
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg (A80)
Trial: 10979057
Drug: Warfarin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin alone (INR maintained at 1.4 or more)
Trial: 10979057
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and aspirin (75 mg/d)
Trial: 9024712
Drug: NFL (Mitoxantrone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFL (Mitoxantrone, 5-fluorouracil, high dose leucovorin)
Trial: 3595067
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide‐5‐mononitrate (IS‐5MN)
Trial: 3595067
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isosorbide‐5‐mononitrate (IS‐5MN)
Trial: 27845765
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (OT) administration
Trial: 22207098
Drug: Daily care
RxNorm normalized name: Aveeno Baby Daily Care Set KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily care activities (washing, dressing, transfer)
Trial: 16138670
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection plus casting
Trial: 11806988
Drug: Conventional 4-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 4-drug induction with cyclophosphamide
Trial: 11806988
Drug: Induction intensification
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction intensification (8-drug consolidation)
Trial: 3224162
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral propranolol every 6 hours (test dosage form)
Trial: 26754586
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pitavastatin daily + intensive lifestyle modification (LSM)
Trial: 25762232
Drug: Daptomycin 10
RxNorm normalized name: daptomycin 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 10 mg/kg/24 h intravenous plus fosfomycin 2 gr/6 g intravenous
Trial: 25762232
Drug: Daptomycin 10
RxNorm normalized name: daptomycin 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin 10 mg/kg/24 h intravenous
Trial: 18806109
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/d) for 6 months
Trial: 18806109
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (10 mg/d) for 6 months
Trial: 12542723
Drug: acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acarbose 100 mg t.i.d.
Trial: 12542723
Drug: glibenclamide 1
RxNorm normalized name: glibenclamide 1.25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide 1 mg t.i.d.
Trial: 9014669
Drug: General prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General prophylaxis with unfractionated heparin
Trial: 9014669
Drug: General prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General prophylaxis with low molecular weight heparin (LMWH)